BIOINFORMATICS/INSILICO R&D

 

 

Here we will be revealing how functional genomics connected with EHR and a host of other metadata are being used to drive forward an end-to-end target discovery process. This along with new toolkits provided to us through the likes of CRISPR allow us to produce truly personalised medicines, reducing costs and getting therapy to patients at new breakneck speeds. We will be dipping into the new structures at various world leading pharma companies to see how the drug and target discovery process is changing and what the next steps are for the industry.
 

THIS YEAR’S WORLD LEADING BIOINFORMATICS/INSILICO R&D SPEAKERS

 

 

 

Bioinformatics & Insilico R&D, Tuesday 2 November 2021

08:40

Opening Remarks

Trevor Howe
09:00

Looking at the bigger picture: How do we make sure that we have the full picture with big data experiments

Joachim Reischl
09:20

Deep Medicine – towards the next generation of software-based precision medicine diagnostics

  • Evolution of precision medicine
  • AI in predicting clinical outcome
  • Software as Medical Device as Companion Diagnostic
Panel discussion
09:40

Essential Tools for Accelerating Pipeline Productivity & Success

What tools are in your toolkit? Join this leading biopharma panel discussion to find out how to give your AI-based drug discovery and development program a competitive edge and increase program success.
10:40

Networking Break

Iris Grossman
Bioinformatics & Insilico R&D
11:40

Data Matters: The Marriage Between Quality and Quantity Translates to Accelerated R&D

Bioinformatics & Insilico R&D
12:00

Sponsor

Philippe Sanseau
Bioinformatics & Insilico R&D
12:20

Analysis of large-scale Omics data

  • Functional Genomics Omics data analyses (e.g., CRISPR)
  • Multi-omics data analyses
  • Case studies
Bioinformatics & Insilico R&D
12:40

Precisionlife Reserved

13:20

Networking Lunch Break

Peter Grandsard
Bioinformatics & Insilico R&D
14:20

Insilco design of therapeutics for well characterised diseases

Bioinformatics & Insilico R&D
15:00

Genomenon Reserved

Bioinformatics & Insilico R&D
15:40

Dotmatics Reserved

16:20

Networking Break

Bioinformatics & Insilico R&D
17:00

BIOGNOSYS Reserved

18:00

Neri & Sons Band & Networking Drinks Reception

last published: 27/Jul/21 14:25

Bioinformatics & Insilico R&D, Wednesday 3 November 2021

Steffen Roellinger
09:00

Decentralised Clinical Trials

  • Discussing the adoption of decentralised clinical trials at Bayer
  • New digital addoption
  • The Bayer trials transformaiton over COVID-19
Andrew Kasarskis
09:00

Digital transformation over COVID-19 – Challenges for the future and perpetuating the efforts

  • COVID-19 lead to digital innovation by necessity, including telehealth, new apps and digital technologies, and data fusion and sharing advances.
  • Large opportunities exist to do much better with learning from data, however.This requires the following operational and cultural change:
-Proactive collection and use of coherent data sets as a baseline for public health and the infrastructure development to support that work.-Recommitment to evidence-based medicine and timely, rigorous assessment of clinical utility through ongoing clinical research with well-powered studies of strong statistical design coupled to careful monitoring of large observational data.
Said Ismail
09:20

Qatar Genome; Big data from an underrepresented region

  • Overview of the Qatar Genome Project (QGP)
  • Contributions to Middle East Genomics
  • QGP role COVID-19 research
  • Strategy for precision medicine implementation
09:20

SevenBridges

Panel discussion
09:40

BC Platforms - Keynote Panel

Paul Agapow
09:40

How to be right: effective use of clinical models and machine learning in the clinic

    There is an increasing demand for a sophisticated model to predict patient outcomes and suggest treatmentsUnfortunately, most proposed clinical models are not fit for purpose, being biased, unvalidated, or irrelevantHere we suggest best practices for the development and deployment of complex ML algorithms, resulting in more successful and effective models
10:20

Networking Break + Speed Networking

Steve Rees
Bioinformatics & Insilico R&D
11:20

Target Identification through Functional Genomics

  • The discovery of novel drug targets is the critical first step in the creation of medicines to treat disease
  • Functional Genomics describes the screening of genome-wide CRISPR libraries in cellular disease models to examine the effect on biology of the deletion or up-regulation of every gene
  • Functional Genomics is being used to identify genes involved in many disease processes
  • Functional Genomics is being used to identify genes that sensitise cells or drive resistance to cancer medicines
Bioinformatics & Insilico R&D
11:40

Sponsor

Jacob Glanville
Bioinformatics & Insilico R&D
12:00

Using computational biology to develop vaccines of the future

Bioinformatics & Insilico R&D
12:20

Sponsor

Fernando Ulloa Montoya
Bioinformatics & Insilico R&D
12:40

Translational genomics for vaccines: Characterizing individual vaccine response and disease heterogeneity

  • Genomics applications in prophylactic and therapeutic vaccines
  • Biomarkers for vaccine protection and patient stratification
13:00

Networking Lunch Break

Monica Wang
Bioinformatics & Insilico R&D
14:00

Overview of Takeda’s Biologics Discovery Platform - End to end – and how its users interact with it.

Bioinformatics & Insilico R&D
14:40

Sponsor

Joanna Betts
Bioinformatics & Insilico R&D
15:00

Integration of genetics and genomics for target identification and clinical translation

Bioinformatics & Insilico R&D
15:20

Sponsor

Morten Sogaard
Bioinformatics & Insilico R&D
15:40

Considerations for target discovery and validation integrating genetics and bioinformatics

16:00

Networking Break

Bioinformatics & Insilico R&D
16:40

Sponsor

Panel discussion
Bioinformatics & Insilico R&D
17:00

Start Up Pitches

18:00

Drinks Reception

last published: 27/Jul/21 14:25

Bioinformatics & Insilico R&D, Thursday 4 November 2021

Scott Chandler
09:00

Genetic Drivers of Response to Immunotherapy: Going Beyond the Tumor

09:20

GenomeSys

Thomas Hach
10:40

The Future of Precision Healthcare – Multi-Omics Humanized

  • Personalization of healthcare, not only of drug treatment, is the future
  • Patient influence, patient data and patient-desired outcomes are the most disruptive factors
  • How can we move from sterile biosignatures to a humanized approach?
last published: 27/Jul/21 14:25

GET INVOLVED AT BIODATA WORLD CONGRESS

 

 

TO SPONSOR


Alistair Wilmot
alistair.wilmot@terrapinn.com
0207 092 1174

 

 

TO SPEAK


Edward Glanville

edward.glanville@terrapinn.com
0207 092 1042

 

 

MARKETING OPPORTUNITIES


Onika Akhtar
onika.akhtar@terrapinn.com
0207 092 1034